NewAmsterdam Pharma Company NV(NAMS) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -2.18 | Insider Own | 35.41% | Shs Outstand | 117.7M | Perf Week | -4.59% |
| Market Cap | 2.33B | Forward P/E | - | EPS next Y | 17.38% | Insider Trans | -0.88% | Shs Float | 77.2M | Perf Month | -13.51% |
| Enterprise Value | 1.70B | PEG | - | EPS next Q | -0.49 | Inst Own | 69.2% | Short Float | 24.67% | Perf Quarter | -30.2% |
| Income | -0.26B | P/S | 327.9 | EPS this Y | -9.77% | Inst Trans | -2.24% | Short Ratio | 13.35 | Perf Half Y | -35.86% |
| Sales | 0.01B | P/B | 3.64 | EPS next 5Y | 37.43% | ROA | -34.16% | Short Interest | 19.05M | Perf YTD | -44.33% |
| Book/sh | 5.37 | P/C | 3.68 | EPS past 3/5Y | -12.98% - | ROE | -36.81% | 52W High | -53.73% ($42.21) | Perf Year | -45.32% |
| Cash/sh | 5.31 | P/FCF | - | Sales past 3/5Y | -39.71% - | ROIC | -41.09% | 52W Low | 2.09% ($19.13) | Perf 3Y | 209.51% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -35.06% | Gross Margin | 96.57% | Volatility(W/M) | 6.52% 5.73% | Perf 5Y | 99.08% |
| Dividend TTM | - | EV/Sales | 238.69 | Sales Y/Y TTM | -88.87% | Oper. Margin | -3432.2% | ATR (14) | 1.24 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 9.03 | EPS Q/Q | -254.88% | Profit Margin | -3644.21% | RSI (14) | 34.96 | Recom | 1.12 |
| Dividend Gr. 3/5Y | - | Current Ratio | 9.03 | Sales Q/Q | -80.67% | SMA20 | -9.52% ($21.58) | Beta | 0.14 | Target Price | $51.27 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/8/5 | SMA50 | -16.62% ($23.42) | Rel Volume | 1.1 | Prev Close | $19.71 |
| Employees | 100 | LT Debt/Eq | 0 | EPS/Sales Surpr. | -9.17% 31.56% | SMA200 | -35% ($30.05) | Avg Volume(3M) | 1.43M | Price | $19.53 |
| IPO | 2021/2/8 | Option/Short | Yes/Yes | Trades | 9091 | Volume | 1,564,233 | Change | -0.91% |
🫀 This is a clinical-stage biopharmaceutical company developing treatments for cardiovascular disease. The company focuses on an oral therapy designed to lower cholesterol and is pursuing commercialization based on Phase 3 clinical trial results. It is a biopharmaceutical firm specializing in cholesterol and cardiovascular therapeutics.
Over the past 1 year, on the lower side
54% below its 1-year high.
Traded about as much as usual. That is 110% of its average volume.
NAMS has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by -9.8% this year.
Tap to view numbers
Relative to sales, it looks expensive
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $32,790. Peers typically go for $1,575.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Bought 5 years ago, your return today would be +99.1%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Short interest is a burden
24.7% of the float is sold short.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #81 of 594 in the industry
Based on market cap of $2B.
NAMS#81 NewAmsterdam Pharma Company NV $2B PER - 
CLDX#82 Celldex Therapeutics Inc $2B PER - 
SLS#83 SELLAS Life Sciences Group Inc $2B PER - 
RXRX#84 Recursion Pharmaceuticals Inc $2B PER - 
AUPH#85 Aurinia Pharmaceuticals Inc $2B PER 7.5 
FAQ
What kind of company is NAMS?
NAMS belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of NAMS?
The market cap of NAMS is approximately $2.3B, ranking 1,914 within its sector.
What is the 52-week high and low for NAMS?
NAMS has recorded a 52-week high of $42.21 and a low of $19.13.
